New York, NY, October 16, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member of its distinguished Board of Directors.
A renowned leader in clinical research and care for lupus and other rheumatologic diseases, Dr. Wallace is Medical Director of the Wallace Rheumatic Study Center and Associate Director of the Rheumatology Fellowship Program at Cedars-Sinai in Los Angeles. With over 40 years of experience, his office manages the care of 1,500 people with lupus, the largest practice of its kind in the United States.
Over his illustrious career, Dr. Wallace has been involved in more than 50 pivotal clinical trials for lupus and is currently conducting six trials. He has published 430 papers in peer-reviewed journals and contributed chapters to nearly 30 books and supplements. His own eight books, three of which are widely accepted authoritative works on lupus including the best known—Dubois Lupus Erythematosus, now in its 9th edition.
“Clinical trials must be designed with the views and needs of real patients in mind. And there is no one with more expertise in treating people with lupus or in planning and conducting clinical trials than Dan Wallace,” said Albert Roy, Lupus Therapeutics Executive Director.
